JT Gains World-First Topical JAK Inhibitor Approval
Japan Nod In Competitive Dermatitis Space
Latest new drug approvals in Japan include the first anywhere for a topical JAK inhibitor and also a marketing clearance for a new contender in the large prostate cancer space.
You may also be interested in...
Top-line Phase III results from Incyte’s TruE-AD2 study of ruxolitinib cream and Eli Lilly’s BREEZE-AD4 and BREEZE-AD5 studies of oral baricitinib show that the compounds achieved primary endpoints in atopic dermatitis, and they may eventually challenge Sanofi’s Dupixent’s growth in the sector.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.